ANNEXON INC

ANNXNASDAQ

🏆 #1984 by market capEarnings Aug 13US Equity

$5.34▼ $0.05 (−0.93%)

🌙 After hours$5.38▲ 0.75%Regular close · extended-hours price shown

1h—

24h▼ 0.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$875M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for ANNX.

Trading Snapshot

Day Range: $5.27 – $5.44
52-Week Range: $2.03 – $7.18
Volume: $2.13B
Avg Volume: $2.10B
Shares Outstanding: 163.8M
Next Earnings: Sep 3, 2026

Fundamentals Snapshot

Annual Revenue: $172M
Last Q Revenue: $40M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.20
Dividend Yield: —

Why Investors Own ANNX

✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
✓Healthy economics — 64% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$172M▼ −0.2% YoY

Gross Margin (TTM)

64.1%▲ +3.5% YoY

Operating Income (TTM)

$22M▼ −0.2% YoY

Free Cash Flow (TTM)

$34M▼ −0.2% YoY

About ANNEXON INC

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

🦦